Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BUB1 | O43683 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3433873 | 1.00 | BUB1 (0.32) | BUB1 | |
| SCHEMBL9007115 | 0.77 | — | — | |
| SCHEMBL31190199 | 0.76 | — | — | |
| SCHEMBL10086876 | 0.74 | — | — | |
| SCHEMBL16467148 | 0.74 | — | — | |
| SCHEMBL8613380 | 0.73 | — | — | |
| SCHEMBL8613387 | 0.73 | — | — | |
| SCHEMBL2860591 | 0.72 | — | — | |
| SCHEMBL6552173 | 0.71 | — | — | |
| SCHEMBL4600649 | 0.69 | KDM4E (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9394273-B2 | Therapeutic prostaglandin receptor agonists | ALLERGAN, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150329518-A1 | THERAPEUTIC PROSTAGLANDIN RECEPTOR AGONISTS | ALLERGAN, INC. | 2015-11-19 | — | — | US | disclosed |
| EP-1819670-B1 | 12-ARYL PROSTAGLANDIN ANALOGS | ALLERGAN INC (US) | 2012-08-08 | — | — | EP | disclosed |
| EP-2265576-A1 | THERAPEUTIC SUBSTITUTED CYCLOPENTANES | Allergan, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| US-7732443-B2 | Therapeutic substituted cyclopentanes | ALLERGAN, INC. | 2010-06-08 | — | — | US | disclosed |
| WO-2009117388-A1 | THERAPEUTIC SUBSTITUTED CYCLOPENTANES | ALLERGAN, INC. (US) | 2009-09-24 | — | — | WO | disclosed |
| US-7427685-B2 | Therapeutic substituted cyclopentanes | ALLERGAN, INC. (US) | 2008-09-23 | — | — | US | disclosed |
| EP-1819670-A1 | 12-ARYL PROSTAGLANDIN ANALOGS | Allergan, Inc. (US) | 2007-08-22 | — | — | EP | disclosed |
| US-20070129552-A1 | Therapeutic Substituted Cyclopentanes | ALLERGAN, INC. | 2007-06-07 | — | — | US | disclosed |
| WO-2006063179-A1 | 12-ARYL PROSTAGLANDIN ANALOGS | ALLERGAN, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129552-A1 | Therapeutic Substituted Cyclopentanes | MCL1, GLI1, BID | BUB1 1076/4885 |
| US-20150329518-A1 | THERAPEUTIC PROSTAGLANDIN RECEPTOR AGONISTS | PTGIR, PTGDR, PTGFR | BUB1 4002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.